Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

http://www.wikidata.org/entity/Q33405181

about

α-Keto phenylamides as P1'-extended proteasome inhibitors Desensitization: Overcoming the Immunologic Barriers to Transplantation Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway Misfolded proteins: from little villains to little helpers in the fight against cancer.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo.Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.Positioning of proteasome inhibitors in therapy of solid malignancies.Variabines A and B: new β-carboline alkaloids from the marine sponge Luffariella variabilis.

P2860

Q27694709-2EEFFEAE-3FF6-4463-AC97-48F36CB9CCA8 Q30397952-767FEFD6-05D8-4F33-9F4A-F89676C9A327 Q34455663-E974EB58-FCAA-45E7-8A8C-A47DBA082933 Q34466592-CF276E68-074C-4CCF-A661-F25A4DBDA127 Q34788381-04C1AE9F-3570-4963-8B67-08F9B927EF24 Q35856827-027D87E7-5DC6-46F7-BABB-189DFFDFE04A Q36413676-ED91F2E0-5FB0-4EED-8DE8-775B356FE590 Q36414426-1409EEE0-F3B7-4106-B0ED-5E672D9AB11B Q37015742-64FCF19A-3685-4931-8C31-C826D8810F93 Q38181445-BE8AE971-E85A-4855-A310-9C9FD68F42E2 Q38444221-1CB7E03A-C8E0-473D-94FF-FBE1E6793FB8 Q39043749-E9679236-353E-4636-88E3-9FDF61EE57F5 Q39084493-E22889F7-C09B-40EF-A6B8-6AA663AC7230 Q39139112-616F326D-74CA-43FA-80ED-74DD1987A692 Q39234159-F0B0104B-EF58-43E7-85A0-E31B9CC7AEE8 Q41620033-516AA42B-6806-4D00-91A6-11CF0518104F Q41770950-247A4FA0-BF75-44FD-BB60-7A1588AFA59E Q42361415-4C5A1080-AF0D-42AA-9F9E-253CE0102B2E Q42755952-B79CE127-6780-48CB-8656-CFE8AE398D0E Q46379792-57C5B807-5743-4216-91D6-6C6914C994D8 Q46667078-C92148A1-9465-42DD-9EB9-101CB71C8048 Q47353792-E78AA3A1-8D3C-43E9-86C8-AC0E229BDCF9 Q50981919-AABCFDB3-2058-442E-BC13-D7BE3022A38C

P2860

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

http://www.wikidata.org/entity/Q33405181

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Carfilzomib: a second-generati ...... d refractory multiple myeloma.

@ast

Carfilzomib: a second-generati ...... d refractory multiple myeloma.

@en

type

label

Carfilzomib: a second-generati ...... d refractory multiple myeloma.

@ast

Carfilzomib: a second-generati ...... d refractory multiple myeloma.

@en

prefLabel

Carfilzomib: a second-generati ...... d refractory multiple myeloma.

@ast

Carfilzomib: a second-generati ...... d refractory multiple myeloma.

@en

P1433

Q33405181-F729AC95-BF55-4C76-AA90-0D90D9EF195C

P1476

Q33405181-C8670EC6-8771-4D35-AA55-F1C913D19D43

P2093

Q33405181-C69BC082-CFE4-45F4-95BE-A10A52B93463

P2860

Q33405181-00B63943-6F69-4FEF-AD39-29083C83D611

Q33405181-043AB7F9-F5B9-40DD-9405-6AE8A5BC7EA4

Q33405181-073AD2F8-08B4-45E6-9DC9-CE8218576389

Q33405181-20FA4902-27EF-4946-B22B-099741B590C0

Q33405181-2F63A67A-DDAD-4965-9DED-919EEBCBC487

Q33405181-52A23EFD-C851-4585-8624-C9C96D837ED7

Q33405181-70F450DB-B960-4432-B328-8E67C64E5FFD

Q33405181-86622879-B1FE-40D5-8FEE-EEAB290FC97C

Q33405181-89817673-76AC-4BE1-9941-BC522049F0CB

Q33405181-95A4EB7F-92E8-4C7A-B81E-784A140D4F31

P304

Q33405181-FC33D50E-7E37-491F-88AF-C494DCA0FCE1

P31

Q33405181-19EAF8D3-E6E1-4CEB-9FAC-E682F2D2920F

P356

Q33405181-C262FA20-A27F-4294-A8F2-059891EFC3AA

P407

Q33405181-B99035C0-86B2-4D2E-9B5A-58023D4F28F2

P433

Q33405181-64FAD5D4-07D8-4404-8982-F195DB906286

P478

Q33405181-47A01874-8487-448C-9AA8-77FAC9B25CA5

P577

Q33405181-05F3AD72-A6A9-4999-B13D-1DD23B4EB27E

P5875

Q33405181-0F376EE9-38BD-4A9C-AAEC-944739F6389B

P698

Q33405181-C9926021-D7A1-4985-9BBA-98F87353ACFC

P356

P1433

Annals of Pharmacotherapy

P1476

Carfilzomib: a second-generati ...... d refractory multiple myeloma.

@en

P2093

Jennifer L Thompson

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

P304

56-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1R561

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234089765

http://www.w3.org/2001/XMLSchema#string

P698

23300152

http://www.w3.org/2001/XMLSchema#string